Reevaluating erythropoiesis-stimulating agents (4)

New England Journal of Medicine

Volumn 362, Issue 18, 2010, Pages 1742-1743

  Kimmel, Paul L ^a   Malozowski, Saul ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; GLUCOSE; HEMOGLOBIN;

ANEMIA; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HORMONE RESISTANCE; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PRIORITY JOURNAL; HUMAN; METABOLISM; NOTE; REFERENCE VALUE;

ANEMIA; ERYTHROPOIETIN; HEMATINICS; HEMOGLOBINS; HUMANS; REFERENCE VALUES;

EID: 77951807851     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1002263     Document Type: Letter

References (4)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
2. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
3. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523-534 (Pubitemid 36951364)
4. Takala J, Ruokonen ED, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999;341:785-792 (Pubitemid 29420473)